Parathyroid Hormone-Related Protein Regulates Cell Survival Pathways via Integrin α6β4-Mediated Activation of Phosphatidylinositol 3-Kinase/Akt Signaling

Vandanajay Bhatia,1 Ramanjaneya V. Mula,1 Nancy L. Weigel,2 and Miriam Falzon1,2

1Department of Pharmacology and Toxicology and 2Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, Galveston, Texas and 3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas

Abstract
Parathyroid hormone-related protein (PTHRP) is expressed by human prostatic tissues and cancer cell lines. PTHrP enhances tumor cell growth and metastasis in vivo and up-regulates proinvasive integrin α6β4 expression in vitro. Hallmarks of malignant tumor cells include resistance to apoptosis and anchorage-independent cell growth. In this study, we used the human prostate cancer cell lines C4-2 and PC-3 as model systems to study the effects of PTHrP on these processes. We report that PTHrP protects these cells from doxorubicin-induced apoptosis and promotes anchorage-independent cell growth via an intracrine pathway. Conversely, autocrine/paracrine PTHrP action increases apoptosis in C4-2 cells and has no effect on apoptosis in PC-3 cells. The intracrine effects of PTHrP on apoptosis are mediated via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. PTHrP also affects the phosphorylation state of Akt substrates implicated in apoptosis suppression, including glycogen synthase kinase-3 and Bad. The prosurvival effects of PTHrP are accompanied by increases in the ratio of antiapoptotic to proapoptotic members of the Bcl-2 family and in levels of c-myc. PTHrP also increases nuclear factor-κB activity via a PI3K-dependent pathway. Integrin α6β4 is known to activate PI3K. Here, we also show that knockdown of integrin α6β4 negates the PTHrP-mediated activation of the PI3K/Akt pathway. Taken together, these observations provide evidence of a link between PTHrP and the PI3K/Akt signaling pathway through integrin α6β4, resulting in the activation of survival pathways. Targeting PTHrP production in prostate cancer may thus prove therapeutically beneficial. (Mol Cancer Res 2009;7(7):1119–31)

Introduction
Prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer-related deaths in males in the United States (1). The prostate is strongly dependent on androgens for normal development and physiologic functions. However, additional factors, including growth factors, neuroendocrine peptides, and cytokines, also play important roles in the prostate (2); one of these factors is parathyroid hormone-related protein (PTHRP). PTHrP is expressed by most fetal and adult tissues, including the prostate. The protein has been localized to normal neuroendocrine cells and the glandular epithelium of normal and benign prostatic hyperplasia tissues (3, 4). Cultured epithelial cells derived from normal and benign prostatic hyperplasia tissues, and immortalized prostate cancer cell lines, secrete PTHrP (5). The progression of normal prostate epithelium to benign prostatic hyperplasia as well as to carcinoma is accompanied by an increase in PTHrP expression (6). PTHrP plays a major role in both the initial osteoblastic phase and the later osteolytic phase, which is characteristic of prostate cancer (7).

Oncogenic cell transformation is a multistage process in which multiple genetic lesions result in alterations in cellular physiology (8). This results in cells acquiring new capabilities, including an increased ability to migrate and invade surrounding tissues and escape apoptotic death (8). Cell migration and invasion involve cell detachment from the extracellular matrix and would result in apoptosis if not accompanied by increased expression of cell survival factors (8). Resistance to apoptosis increases in prostate cancer cells with increasing metastatic potential (9, 10). Specifically, the term “anoikis” describes apoptosis induced by loss of anchorage during dissemination in lymph or blood (11). This term was originally defined by Frisch to describe apoptotic cell death as a consequence of insufficient cell-matrix interactions (11) and has since been recognized as a significant player in tumor metastasis and angiogenesis (11-13).

Because prostate cancer progression is accompanied by increased PTHrP expression, and given the role of PTHrP in prostate cancer metastasis, in this study, we asked whether PTHrP plays a role in prostate cancer cell survival and anchorage-independent cell growth and investigated the mechanisms involved. We used the C4-2 and PC-3 cell lines as model systems. The C4-2 cell line is a second-generation LNCaP subline that is androgen-independent and metastasizes to the lymph node and bone when injected orthotopically into nude mice (14, 15). C4-2 cells produce mixed lytic/blastic lesions (7).
The androgen-independent PC-3 cell line was initiated from a bone metastasis and produces predominantly lytic lesions.

PTHrP is only detected in the circulation in normal subjects during pregnancy and lactation and in cancer patients with the accompanying syndrome of humoral hypercalcemia of malignancy. In normal subjects and in cancer patients in the absence of humoral hypercalcemia of malignancy, PTHrP exerts its effects via autocrine/paracrine and intracrine pathways. The mature PTHrP species is post-translationally processed to NH2-terminal, mid-region, and COOH-terminal secretory forms (Fig. 1A; 16).

NH2-terminal PTHrP exerts its autocrine/paracrine effects via interaction with the parathyroid hormone/PTHrP 1 receptor (PTH1R; ref. 17). Autocrine/paracrine PTHrP action via the PTH1R has been reported to inhibit or enhance cell proliferation in a cell type-specific manner (18-21).

Intracrine PTHrP action increases C4-2 and PC-3 cell proliferation (21). PTHrP also increases cell migration and invasion and up-regulates proinvasive integrin α6β4 expression via an intracrine pathway (23, 24).

The molecular mechanisms that control the susceptibility of cells to anoikis involve the overexpression of antiapoptotic factors and/or the activation of several kinases, including phosphatidylinositol 3-kinase (PI3K; ref. 25). This pathway plays
a central role in apoptosis and in the anchorage-independent survival of cancer cells (25). In this study, we also asked whether the prosurvival effects of PTHrP are mediated via the PI3K pathway. Because integrin \(\alpha_6\beta_4\) is known to signal synergistically with growth factor receptors to activate the PI3K pathway (26), we also asked whether up-regulation of integrin \(\alpha_6\beta_4\) expression by PTHrP (24, 27, 28), in turn, activates PI3K. PTHrP is involved in both osteolytic and osteoblastic phases of prostate cancer, so elucidating the mechanisms via which it exerts its effects in prostate cancer may identify therapeutically useful targets for drug development.

Results
Characterization of C4-2 and PC-3 Cell Lines Overexpressing Wild-type or NLS-Mutated PTHrP

Cell survival plays a critical role in cancer cell progression. PTHrP exerts its effects via autocrine/paracrine and intracrine pathways. In this study, we asked whether PTHrP alters prostate cancer cell survival and the pathways involved. We therefore established C4-2 and PC-3 cells overexpressing wild-type or NLS-mutated PTHrP. Empty vector transfecants served as controls. These cells were characterized in terms of PTHrP mRNA and cellular protein levels as well as secreted protein levels.

Transfecting C4-2 cells with the constructs expressing wild-type or NLS-mutated PTHrP resulted in significant (~20- to 25-fold) increases in PTHrP mRNA levels and secreted PTHrP levels when compared with control cells (Fig. 1B and C). Total and cytoplasmic PTHrP levels were elevated in cells overexpressing wild-type or NLS-mutated PTHrP when compared with control cells (Fig. 1D). Nuclear PTHrP levels were significantly higher in wild-type PTHrP-overexpressing cells compared with NLS-mutated PTHrP-overexpressing cells or control cells (Fig. 1D). Reprobing the blots with antibodies specific for lamin B1 and \(\beta\)-actin, specific for nuclear and cytoplasmic markers, respectively, confirmed that there was no cross-contamination of the nuclear or cytoplasmic fractions (data not shown). Total cellular PTHrP levels were higher in cells overexpressing wild-type PTHrP compared with NLS-mutated PTHrP-overexpressing and control cells (Fig. 1D). An ~18 kDa PTHrP isoform was present in total, cytoplasmic, and nuclear fractions; this moiety represents a processed form of PTHrP (29). There was no difference in PTHrP mRNA and secreted protein levels in control versus parental cells (data not shown). The PC-3 clones overexpressing wild-type or NLS-mutated PTHrP have been described (24). PTHrP mRNA and secreted protein levels were 8- to 10-fold higher in PC-3 than in C4-2 cells. However, Western blot analysis showed that total cellular PTHrP levels were only ~2- to 3-fold higher in PC-3 versus C4-2 cells (data not shown), indicating that a large proportion of PTHrP synthesized by the cell is secreted.

We also ascertained that overexpression of wild-type or NLS-mutated PTHrP does not alter PTH1R expression and activity and therefore that differences in the response of PTHrP-overexpressing cells versus control cells are not due to differences in PTH1R expression and/or activity. The PTH1R was expressed at low levels in control C4-2 cells; PC-3 cells expressed ~15-fold higher PTH1R levels (data not shown). In Fig. 2, data are presented for C4-2 cells; PC-3 cells showed the same profile. Overexpressing wild-type or NLS-mutated PTHrP did not alter PTH1R mRNA levels (Fig. 2A). To compare PTH1R activity, we measured cyclic AMP (cAMP) accumulation in response to human PTHrP(1-34). C4-2 cells showed an increase in cAMP production in response to this peptide (Fig. 2B). The ability of PTHrP(1-34) to induce a cAMP response was dose related between 0.1 and 100 nmol/L; cAMP production reached a plateau at 10 nmol/L (Fig. 2B). There was no difference in the response to PTHrP(1-34) in control cells and in cells overexpressing wild-type or NLS-mutated PTHrP (Fig. 2B). As a control, cells were treated with the structurally unrelated peptides salmon calcitonin and secretin, which do not interact with the PTH1R. These peptides did not affect PTH1R activity in control or PTHrP-overexpressing cells (data not shown). Similarly, two PTHrP antagonists, [Leu\(^{11}\), d-Trp\(^{12}\)]hPTHrP-(7-34) amide and [Asn\(^{10}\), Leu\(^{11}\)]hPTHrP-(7-34) amide, and the parathyroid hormone antagonist PTH(3-34) did not

FIGURE 2. Parathyroid hormone 1 receptor expression (A) and activity (B) in C4-2 cells overexpressing wild-type or NLS-mutated PTHrP. A, mRNA levels were measured by reverse transcription/real-time PCR. Values are expressed relative to the corresponding V value, set arbitrarily at 1.0. Each bar is the mean ± SEM of three independent experiments. Data for two independent clones are presented. B, Dose-dependent cAMP response of C4-2 cells. Cells were treated with human PTHrP (1-34). cAMP activity was measured using the Parameter cAMP assay kit. Each point is the mean ± SEM of three independent experiments for each of two independent clones. A and B, WT, wild-type PTHrP-overexpressing cells; V, empty vector controls; ∆NLS, NLS-mutated PTHrP-overexpressing cells.
increase cAMP production in any of the cells tested (data not shown).

**Wild-type PTHrP Supports Anchorage-Independent Cell Growth**

To investigate the effect of PTHrP on anchorage-independent cell growth, C4-2 and PC-3 cells overexpressing wild-type or NLS-mutated PTHrP were grown in soft agar for 15 days. Data are shown for C4-2 cells; a similar profile was obtained with PC-3 cells, except that the size and number of colonies obtained with PC-3 cells were ∼3-fold greater than those obtained with C4-2 cells. Wild-type PTHrP facilitated soft-agar clone formation. Thus, overexpressing PTHrP increased both the number and the size of the colonies in soft agar (Fig. 3). NLS-mutated PTHrP had no effect on the number and size of colonies in soft agar; there was no significant difference in these parameters between cells transfected with NLS-mutated PTHrP and cells transfected with the empty vector (Fig. 3). Increasing the incubation time from 15 to 21 days did not increase the number of colonies formed by any of the clones (data not shown). There was no significant difference in colony formation between parental and empty vector transfectants (data not shown).

**Wild-type PTHrP Protects C4-2 and PC-3 Cells from Doxorubicin-Induced Apoptosis**

To ask whether PTHrP modulates apoptosis, we compared this parameter in cells overexpressing wild-type PTHrP versus control cells. In C4-2 cells, the basal level of apoptosis was not significantly different in PTHrP-overexpressing and control cells (Fig. 4A). In PC-3 cells, PTHrP caused a small, but significant, decrease in basal apoptosis (Fig. 4B). Wild-type PTHrP protected both C4-2 and PC-3 cells against apoptosis induced by the DNA-intercalating agent doxorubicin. Thus, treating C4-2 cells with 0.3 μg/mL doxorubicin for 16 h induced apoptosis in both PTHrP-overexpressing and control cells (Fig. 4A). However, the degree of apoptosis induced in control cells was significantly higher than that in wild-type PTHrP-overexpressing cells (Fig. 4A). Similar effects were observed when cells were treated with 0.1 μg/mL doxorubicin, although the overall degree of apoptosis induced was significantly lower (Fig. 4A). Similar results were obtained in PC-3 cells, although a 72 h treatment was required to induce apoptosis (Fig. 4B). To determine whether the antiapoptotic effects of PTHrP are mediated via an intracrine pathway, doxorubicin-induced apoptosis was compared in cells overexpressing wild-type and NLS-mutated PTHrP. NLS-mutated PTHrP did not protect cells from apoptosis (Fig. 4A and B).

The autocrine/paracrine effects of PTHrP are mediated via interaction with the PTH1R. To assess the contribution of autocrine/paracrine signaling to the effects of PTHrP on apoptosis, parental C4-2 and PC-3 cells were treated with an anti-PTHrP (1-34) antibody or an anti-PTH1R antibody (at a concentration of 1 or 2 μg/mL) to neutralize the autocrine/paracrine effects of PTHrP. Treatment of C4-2 cells with either of these antibodies did not enhance doxorubicin-induced apoptosis; rather, it caused an ∼40% decrease in apoptosis compared with cells treated with control IgG (Fig. 4C). These antibodies had no effect on apoptosis of PC-3 cells (data not shown). To confirm these results, cells were transfected with a small interfering RNA (siRNA) targeting the PTH1R and then treated with doxorubicin (0.3 μg/mL) to induce apoptosis. To eliminate

**FIGURE 3.** Effects of PTHrP on anchorage-independent cell growth. Assays to determine colony formation in soft agar were performed in 60 mm dishes containing a bottom layer consisting of 1.5 ml culture medium plus 0.4% (w/v) agar. Cells (1 × 10^4) were plated in a top layer of 0.3% agar. A. After 2 wk in culture, the plates were photographed at 40 × magnification, and clone size was measured using the ImageJ software (NIH). B. Photographs were also taken at 10 × magnification to measure clone frequency. C. Colony size. Each bar is the mean ± SEM of 20 colonies for each of two independent clones overexpressing WT PTHrP (WT) or NLS-mutated PTHrP (ΔNLS), or transfected with empty vector (V). D. Average number of colonies. Each clone in focus >50 μm in size was measured. Each bar is the mean ± SEM of three fields per plate for each of the cell lines described in C, C and D. *, significantly different from the control (V) value (P < 0.001).
the potential for off-target effects, two independent PTH1R-specific siRNAs were used. Transfection with either of the two PTH1R-specific siRNAs caused a ∼75% decrease in PTH1R mRNA levels compared with the nontarget control (NTC; as measured by reverse transcription/real-time PCR; data not shown). Suppressing PTH1R expression in C4-2 cells caused an ∼35% decrease in doxorubicin-induced apoptosis compared with the NTC controls similarly treated with doxorubicin (Fig. 4D). Suppression of PTH1R expression had no effect on apoptosis in PC-3 cells (data not shown).

**Wild-type PTHrP Alters the Expression of Apoptosis-Regulating Proteins of the Bcl-2 Family**

The Bcl-2 family of proteins plays an important role in the regulation of apoptosis; different members of this family either inhibit or promote apoptosis (30). Figure 5A shows that the prosurvival effects of wild-type PTHrP in C4-2 cells were accompanied by an increase in the levels of the antiapoptotic proteins Bcl-2 and BclXL, as well as p-Bad and a decrease in the levels of Bax, which exert proapoptotic effects. Conversely, NLS-mutated PTHrP had minimal effects on the levels of Bcl-2, BclXL, Bax, and p-Bad (Fig. 5A). There was no difference in the levels of any of the proteins measured in control versus parental cells (data not shown). Similar effects of PTHrP on Bcl-2, BclXL, Bax, and p-Bad levels were observed in PC-3 cells (data not shown).

Heterodimerization between proapoptotic and antiapoptotic members of the Bcl-2 family and the relative levels of the two types of proteins play a role in the susceptibility to apoptosis (30). Figure 5B and C show that wild-type, but not NLS-mutated, PTHrP expression is associated with an increased ratio of antiapoptotic (Bcl-2 and BclXL) to proapoptotic (Bax) proteins.

**PTHrP Modulates the Levels of p-Akt, p-glycogen Synthase Kinase-3, and c-myc**

The PI3K/Akt pathway plays a major role in cancer cell survival (25). We therefore compared the levels of p-Akt in C4-2 and PC-3 cells overexpressing wild-type or NLS-mutated PTHrP. We observed a correlation between the expression of wild-type PTHrP and p-Akt levels (Fig. 5D; data not shown). Conversely, p-Akt levels in cells overexpressing NLS-mutated PTHrP were comparable with those in control cells (Fig. 5D; data not shown). PTHrP had no effect on total Akt levels (Fig. 5D; data not shown).
Analysis of the effect of PTHrP overexpression on downstream signaling molecules of the Akt pathway involved in cell survival revealed that wild-type PTHrP also induced phosphorylation of glycogen synthase kinase (GSK)-3β in C4-2 cells, resulting in inhibition of its activity. NLS-mutated PTHrP had no effect on GSK-3β phosphorylation (Fig. 5D). Wild-type, but not NLS-mutated, PTHrP expression was also linked to elevated levels of c-myc (Fig. 5D). Similar effects were observed in PC-3 cells (data not shown).

**Increased Cell Survival in Wild-type PTHrP-Overexpressing Cells Is Mediated via the PI3K Pathway**

We next asked whether regulation of the PI3K pathway by PTHrP plays a role in the observed antiapoptotic effects of PTHrP. For this purpose, PI3K levels and activity were suppressed by transfection with siRNAs targeting the p110α subunit or by treating with the PI3K inhibitor LY49002 (25 or 50 μmol/L). Transfecting C4-2 cells with the p110α siRNA caused a significant decrease in p110α mRNA (Fig. 6A) and protein levels (Fig. 6B), which were accompanied by significant decreases in the levels of p-Akt (Fig. 6B). Treating C4-2 and PC-3 cells with LY49002 also caused a significant decrease in p-Akt levels (data not shown).

Doxorubicin (0.3 μg/mL) was more effective in inducing apoptosis in control cells and in cells overexpressing NLS-mutated PTHrP than in cells overexpressing wild-type PTHrP (Figs. 4 and 6C and D). Inhibiting PI3K activity in C4-2 cells by transfection with p110α siRNA (in the absence of doxorubicin) caused a significant increase in apoptosis in the control cells and the cells overexpressing both wild-type and NLS-mutated PTHrP (Fig. 6C). Down-regulation of PI3K activity by transfection with the siRNA targeting p110α abolished the differences in the extent of apoptosis induced by doxorubicin in wild-type PTHrP-overexpressing versus control cells (Fig. 6C). Thus, the degree of apoptosis, expressed as a ratio for untreated versus doxorubicin-treated cells, was not significantly different in control and PTHrP-overexpressing cells transfected with the p110α siRNA (2.3 for p110α transfecitants in wild-type PTHrP-overexpressing cells versus 2.4 for p110α transfecitants in control cells; Fig. 6C). In cells transfected with the NTC siRNA, this ratio was significantly higher in control cells (4.5) than in cells overexpressing wild-type PTHrP (1.9; Fig. 6C). Cells overexpressing NLS-mutated PTHrP presented the same profile as the control cells (Fig. 6C). A similar profile was observed in both C4-2 and PC-3 after treating with LY49002, in that suppression of PI3K activity negated the differences in sensitivity.
to doxorubicin of PTHrP-overexpressing versus control cells (Fig. 6D; data not shown).

**PTHrP Up-Regulates Nuclear Factor-κB Transcriptional Activity in a PI3K-Dependent Manner**

PI3K signaling activates the nuclear factor-κB (NF-κB) pathway, leading to enhanced cell survival (31). Here, we show that transcriptional activity from a NF-κB reporter construct is significantly higher in PTHrP-overexpressing cells than in control cells (Fig. 6E). Treating C4-2 cells with LY49002 (25 or 50 μmol/L) caused a significant decrease in NF-κB transcriptional activity in PTHrP-overexpressing cells, such that there was no significant difference in promoter activity in PTHrP-overexpression and control cells after LY204002 treatment (Fig. 6E; data not shown). The decrease in promoter activity in control cells was significantly less than that in PTHrP-overexpressing cells after LY49002 treatment (Fig. 6E; data not shown).

**Integrin αβ4 Expression Is Required for the PTHrP-Mediated Activation of PI3K**

The data presented above indicate that PTHrP activates the PI3K pathway via an intracrine mechanism of action. We have shown previously that nuclear PTHrP is required for induction of integrin α6 and β4 expression at both mRNA and protein levels (23, 24). Because it has been shown that integrin α6β4 signals synergistically with growth factor receptors to activate the PI3K pathway (26), here we asked whether activation of PI3K in wild-type PTHrP-overexpressing cells occurs as a result of up-regulation of integrin α6β4 expression. The expression of these integrin subunits was suppressed using siRNAs. In cells transfected with the NTC siRNA, integrin α6 and β4 mRNA levels were higher in wild-type PTHrP-overexpressing cells than in control cells (Fig. 7A and B). Deletion of the NLS negated the effects of PTHrP on integrin expression (Fig. 7A and B). After transfection with the integrin α6- or β4-specific

---

**FIGURE 6.** A to D. Effect of suppression of PI3-K activity on apoptosis after doxorubicin treatment of control C4-2 cells and C4-2 cells overexpressing wild-type or NLS-mutated PTHrP. A. Reverse transcription/real-time PCR analysis for p110α mRNA levels in cells transfected with siRNA targeting the p110α subunit of PI3-K. Each bar is the mean ± SEM of two experiments for each of two independent clones, each transfected with one of two independent siRNAs. B. Western blot analysis for p110α, p-Akt and total Akt in cells transfected with siRNA targeting p110α. With each group of transfectants, 1 and 2 refer to two independent clones. C. Effect of suppression of PI3-K activity by transfection with an siRNA targeting p110α on apoptosis induced by doxorubicin (0.3 μg/ml). NTC, transfected with non-target control. Each bar is the mean ± SEM of two experiments for each of two independent clones, each transfected with one of two independent siRNAs. D. Effect of LY49002 (25 μM) treatment on doxorubicin-induced apoptosis. Each bar is the mean ± SEM of three experiments for each of two independent clones. C and D, WT, wild-type PTHrP-overexpressing cells; ΔNLS, NLS-mutated PTHrP-overexpressing cells; V, empty vector-transfected cells; - dox, treated with doxorubicin; + dox, untreated control. The ratio of the absorbance [405 nm] in the presence and absence of doxorubicin is indicated under each set of bars. #, significantly different from the respective - dox control; *, significantly different from the respective p110α siRNA-transfected cells (C) or LY49002-treated cells (D; P < 0.001). E. Effect of LY49002 on NF-κB activity in control and wild-type PTHrP-overexpressing C4-2 cells. Luciferase activity was measured in empty vector-transfected (V) and PTHrP-overexpressing (WT) C4-2 cells treated with LY490002 as described in D. Values were normalized to Renilla luciferase activity. Each bar is the mean ± SEM of three experiments for each of two independent clones. *, significantly different from the untreated V value; #, significantly different from the respective untreated value (P < 0.001).
siRNAs, there was a significant decrease in the mRNA levels for the corresponding subunit (Fig. 7A and B). The mRNA levels of both integrin α6 and β4 subunits were suppressed in cells cotransfected with siRNAs targeting both subunits (Fig. 7A and B).

Cell-surface integrin α6 and β4 protein levels were also significantly higher in wild-type PTHrP-overexpressing cells but not in NLS-mutated PTHrP-overexpressing cells (Fig. 7C). Transfection with the integrin α6 siRNA caused a significant decrease in the cell-surface levels of both α6 and β4 subunits (Fig. 7C). Transfection with the integrin β4 subunit also caused a significant decrease in α6 and β4 levels (Fig. 7C). Because the α6 subunit can dimerize with both β1 and β4 subunits (32), these data indicate that, in C4-2 cells, the preferential partner for integrin α6 is the β4 subunit.

Transfection of wild-type PTHrP-overexpressing cells with the siRNA targeting the integrin α6 and/or β4 subunit negated the PTHrP-mediated increase in p-Akt levels (Fig. 7D; data...
not shown). p-Akt levels were higher in wild-type PTHrP-overexpressing cells transfected with NTC (Fig. 7D). Transfection with the integrin α6 and/or β4 siRNAs had no effect on total Akt levels (Fig. 7D; data not shown).

Discussion

Multiple studies have shown that PTHrP expression is increased in prostate cancer cells compared with normal prostate epithelium and benign prostatic hyperplasia (5, 6). PTHrP also plays a role in the development of the osteoblastic/osteolytic lesions that accompany prostate cancer (7). However, the consequences of PTHrP dysregulation in prostate cancer have not yet been fully elucidated. Our main findings are that intracrine PTHrP increases anchorage-independent cell growth, a hallmark of malignant tumor cells (33). Given the correlation between anchorage-independent growth in vitro and cellular tumorigenicity in nude mice, these findings may explain the consequences of PTHrP expression in prostate cancer. Wild-type, but not NLS-mutated, PTHrP also activates Akt, a downstream effector of the PI3K pathway. Notably, the prosurvival effects of intracrine PTHrP are mediated via the PI3K pathway, and PI3K signaling in turn is dependent on expression of integrin αβ3.

The ability of cells to migrate and invade through the basement membrane into surrounding tissues is one of the essential hallmarks of cancer and is a necessary step for local tumor progression and metastatic spread. Migration and invasion require that a cell acquires anchorage independence. This property of cancer cells has been recognized as a necessity for cell transformation for many years (33). Here, we report that PTHrP increases C4-2 and PC-3 cell growth as colonies in soft agar in the absence of adhesion to the extracellular matrix. Anchorage independence can lead to apoptosis if not counterbalanced by increased survival (8). In particular, anoikis, a term that describes apoptosis induced by loss of anchorage, is known to limit the spread of cells outside the tissue environment (11). Cancer cells are more anoikis-resistant than their normal counterparts, and the level of anoikis correlates with in vivo tumorigenicity and metastatic capability (13, 34). One mechanism via which cancer cells overcome anoikis is through the overexpression of antiapoptotic factors, such as members of the Bcl-2 family (30, 35). Multiple studies have shown that modulation of the expression of these proteins plays a role in resisting anoikis (30, 35). Here, we show that PTHrP increases the ratio of antiapoptotic (Bcl-2 and BclXL) to proapoptotic (Bax) proteins in the cell. Levels of p-Bad are increased in PTHrP-overexpressing cells. p-Bad is thought to bind to the 14-3-3t proteins in the cell. Levels of p-Bad are also increased in PTHrP-overexpressing cells. p-Bad is thought to bind to the 14-3-3t proteins in the cell.

Androgen deprivation therapy is widely used to treat patients with advanced prostate cancer (37). However, this treatment is not curative, because when tumors eventually recur, they are typically less differentiated and more metastatic than the parent androgen-sensitive tumors (38, 39). The emergence of hormone-refractory disease does not signify a lack of dependence on androgen receptor signaling (40), and it has been shown that the PI3K signaling pathway plays a central role in promoting androgen independence in an androgen receptor-dependent manner (40). This pathway has also been linked to protection from anoikis (25, 41, 42). In this study, we show that PTHrP increases p-Akt levels and protects against doxorubicin-induced apoptosis through the PI3K/Akt signaling pathway (Fig. 8). We also report that Akt activation in wild-type PTHrP-overexpressing cells is accompanied by increased phosphorylation and therefore inactivation of GSK-3 (Fig. 8). GSK-3 phosphorylates c-myc and targets it to the ubiquitin-proteasome pathway (43). Thus, the observed increase in c-myc levels in wild-type PTHrP-overexpressing cells may also be mediated via the PI3K/Akt pathway. These results therefore establish PI3K signaling as one of the primary mediators of PTHrP-enhanced cell survival under conditions of cell stress.

The effects of PTHrP on anoikis and on the expression of members of the Bcl-2 family of proteins may also be mediated via activation of the PI3K pathway. PI3K signaling is known to activate the NF-κB pathway, leading to the survival of cells in suspension (31). Here, we show that PTHrP activates the NF-κB pathway in a PI3K-dependent manner. Several genes with antiapoptotic properties that are regulated by NF-κB have been identified; these include Bcl-2 and BclXL (31). The increase in p-Bad in PTHrP-overexpressing cells is also likely mediated via the PI3K/Akt pathway, because Akt has been reported to phosphorylate Bad (36, 44).

PTHRP functions via both autocrine/paracrine and intracrine pathways (16, 18, 22). Here, we report that the intracrine pathway appears to mediate the antiapoptotic effects of PTHrP, because deleting the NLS negates the protective effect of PTHrP.
against doxorubicin-mediated apoptosis, and there is no significant difference in the levels of members of the Bcl-2 family and in the ratio of antiapoptotic to proapoptotic proteins in control versus NLS-mutated PTHrP-overexpressing cells. Moreover, we show that neutralizing autocrine/paracrine PTHrP action in C4-2 cells using PTHrP- or PTH1R-specific antibodies or siRNAs directed to PTH1R results in decreased, rather than increased, apoptosis. These data suggest that autocrine/paracrine PTHrP action exerts a proapoptotic effect in these cells. PTHrP(1-87) has also been detected in the nucleus of the prostate cancer cell lines PC-3 and PPC-1, resulting in elevated interleukin-8 secretion and increased cell proliferation (45). However, in this study, we did not observe any effects of PTHrP deleted over the NLS (amino acids 88-91 and 102-106) on C4-2 or PC-3 cell apoptosis. PTHrP(1-87) may thus affect cell proliferation but not apoptosis.

The magnitude of the increase in PTHrP secretion in PTHrP-overexpressing versus control cells (~25-fold) is greater than that for PTHrP retained in the cell (5- to 10-fold; Fig. 1), indicating that a greater proportion of the PTHrP generated by the cell is secreted. It therefore appears that relatively small changes in nuclear PTHrP levels may be enough to exert significant effects in the cell. Translocation of PTHrP into the nucleus is cell cycle dependent and involves phosphorylation by p34cdc2 at Thr(35) immediately upstream of the NLS. Phosphorylation results in cytoplasmic retention/nuclear exclusion (46). Although no studies have directly addressed whether exertion of environmental pressure on the cells influences the ratio of secreted to internalized PTHrP, factors that alter cytoplasmic PTHrP levels may indirectly affect its secretion.

Nuclear PTHrP staining has been detected in several tumors, including those of the prostate (reviewed in ref. 47). However, secreted PTHrP levels in vivo can only be measured in cases of humoral hypercalcemia of malignancy, which is not prevalent in prostate cancer patients. Therefore, the relative contribution of the autocrine/paracrine versus the intracrine pathway of PTHrP action in patients is not clearly delineated. However, animal studies show a role for intracrine PTHrP action in vivo, in wild-type, but not NLS-mutated, PTHrP increases C4-2 xenograft growth in nude mice; this effect is accompanied by increased nuclear PTHrP immunostaining. Recently, it has also been shown that knock-in mice expressing PTHrP deleted over the NLS/COOH-terminal domain exhibit retarded growth, early senescence, and malnutrition, leading to a rapid demise postnatally (48). Taken together, these studies underline the importance of intracrine PTHrP action in vitro and in vivo.

In this and previous studies, we show that PTHrP up-regulates integrin α6 and β4 expression at the mRNA and protein levels, with intracrine PTHrP action playing a major role in this effect (23, 24). Integrin α6β4 signals synergistically with growth factor receptors, such as ErbB2, ErbB3, and c-Met (49-51), resulting in activation of the PI3K pathway (26). Here, we show that integrin α6β4 expression is required for activation of PI3K by PTHrP, because PTHrP fails to increase p-Akt levels in wild-type PTHrP-overexpressing cells with suppressed integrin α6 or β4 expression (Fig. 7D). We have shown previously that the prosurvival and promigration effects of PTHrP in MDA-MB-231 cells are mediated via up-regulation of integrin α6β4 expression (52). We therefore propose the following model for intracrine PTHrP action (Fig. 8). PTHrP increases the expression of integrin α6β4 at the mRNA and protein levels, which results in increased integrin α6β4 cell-surface levels. Integrin α6β4 signals synergistically with growth factor receptors, resulting in activation of the PI3K/Akt pathway and increased cell survival.

In conclusion, the results presented here show that PTHrP increases cell survival and anchorage-independent cell growth via an intracrine pathway. The protective effects of PTHrP against doxorubicin-induced cell apoptosis are mediated through the PI3K/Akt pathway and downstream effectors of Akt including GSK-3β and c-myc as well as by modulating the expression of members of the Bcl-2 family of proteins. These results establish Akt signaling as one of the primary mediators of PTHrP-enhanced cell survival under conditions of cellular stress, with integrin α6β4 providing the link between PTHrP and PI3K/Akt. Strategies aimed at decreasing PTHrP production in prostate cancer may thus provide therapeutic benefits.

Materials and Methods

Materials

Fetal bovine serum (FBS) was obtained from Atlanta Biologicals. Tissue culture supplies were purchased from Life Technologies. Antibodies for Western blot analysis were obtained from Santa Cruz Biotechnology and Cell Signaling Technology. The R-phycoerythrin-conjugated anti-α6 (clone GoH3) and anti-β4 antibody (clone 439-9B), as well as the respective isotype control antibodies, were obtained from Pharmingen. The siRNAs targeting the p110α subunit of PI3K, PTH1R, and the integrin α6 and β4 subunits, as well as the NTC siRNA, were purchased from Dharmacon. Doxorubicin and LY49002 were purchased from Calbiochem. The Parameter cAMP assay kit was purchased from R&D Systems.

Plasmid Constructs

A cDNA encoding human PTHrP (obtained from Genentech) was cloned into the EcoRI and HindIII sites of the expression vector pcDNA3.1(+) (Invitrogen). This construct was used to prepare the PTHrP construct deleted over the NLS (amino acids 88-91 and 102-106). These constructs have been described (21). These constructs, as well as the empty vector control pcDNA3.1(+), were transfected into C4-2 and PC-3 cells by electroporation. The construct containing the NF-κB site in the context of the -162/+44 human IL-8 promoter, cloned upstream of the luciferase reporter (hIL-8/LUC), has been described (53).

Cell Culture and Transfection

C4-2 cells were purchased from UroCor and grown at 37°C in humidified 95% air/5% CO2 in RPMI 1640 containing 10% FBS and L-glutamine. PC-3 cells were purchased from the American Type Culture Collection and grown at 37°C in humidified 95% air/5% CO2 in Ham’s F-12 medium supplemented with 10% FBS and L-glutamine. The cells were stably transfected with the PTHrP constructs or with the empty vector by electroporation. Two days after transfection, 600 μg/mL G418 (geneticin; Life Technologies) was added, and resistant

---

1 Bhatia et al., unpublished observations.
clones were selected. Single clones of stably transfected cells, isolated by limiting dilution in 96-well plates, were transferred to individual flasks and cultured in medium containing 150 μg/mL G418. Individual clones overexpressing wild-type or NLS-mutated PTHrP were tested for PTHrP mRNA levels by reverse transcription/real-time PCR (27) and for PTHrP secretion using an immunoradiometric assay (Diagnosics Systems Laboratories; ref. 20). The PC-3 clones have been described (21, 24). For assays to measure NF-κB promoter activity, cells (1 × 10⁵) were plated into 6-well dishes. After 48 h, the cells were transfected with 100 ng DNA using Lipofectamine (Invitrogen). After 4 h, the medium was replaced with complete medium containing LY49002 (25 or 50 μmol/L). Luciferase activity was measured after 24 h using the Luciferase Dual-Assay kit (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity.

Measurement of Intracellular cAMP Levels

Cells were plated in 24-well dishes at 5 × 10⁴ per well. When the cells were ~90% confluent, they were treated for 20 min with human PTHrP(1-34) (concentration, 0.1-100 nmol/mL) or the PTHrP antagonists [Leu¹¹, d-Trp¹²]hPTHrP-(7-34) amide and [Asn¹⁰, Leu¹¹]hPTHrP-(7-34) amide (25 and 75 nmol/L). Salmon calcitonin and secretin (25 and 75 nmol/L) were used as negative controls. The supernatant was then collected, and the protein concentration of the harvested cell monolayer was determined using the Bio-Rad protein assay. For assays to measure NF-κB promoter activity, cells (1 × 10⁵) were plated into 6-well dishes. After 48 h, the cells were transfected with the integrin α6 plus β4 subunits (100 nmol/L; Dharmacon). In some experiments, the cells were transfected with the integrin α6 plus integrin β4 siRNAs. To eliminate the potential for off-target effects, two independent siRNAs were used. As a control, cells were transfected with ON-Target plus NTC siRNAs. Transfections were done using the DharmaFECT 3 transfection reagent (Dharmacon) following the manufacturer’s protocol. To measure the mRNA levels, the cells were harvested 48 h after transfection. To measure protein levels, the cells were harvested 72 h after transfection and processed for Western blot analysis.

Induction of Cell Apoptosis

Cells were plated in 96-well dishes (1 × 10⁴ per well) in medium containing 10% FBS. After 48 h, the cells were treated with doxorubicin (Calbiochem) at 0.1 or 0.3 μg/mL for 16 h (C4-2 cells) or 0.3 μg/mL for 72 h (PC-3 cells) to induce apoptosis. In some experiments, the cells were transfected with siRNA targeting the p110α subunit of PI3K, or the PTH1R, or with a NTC siRNA (100 nmol/L; Dharmacon) 48 h after plating. Doxorubicin (0.3 μg/mL) was then added 48 h after transfection. In another set of experiments, the cells were treated with monoclonal antibodies raised against PTHrP(1-34) (Santa Cruz Biotechnology) or the PTH1R(143-169) (Calbiochem). IgG was used as a control. After 48 h, the cells were treated with 0.3 μg/mL doxorubicin. For LY49002 treatment, cells were grown to 80% confluence and then treated with LY49002 (25 or 50 μmol/L) for 4 h followed by doxorubicin (0.3 μg/mL). Apoptosis was measured after 16 h (C4-2 cells) or 72 h (PC-3 cells) using the Cell Death Detection ELISA PLUS kit (Roche Applied Science). The cells were lysed for 30 min at room temperature by incubation with 200 μL lysis buffer. After centrifugation (10 min at 200 × L), 20 μL of the supernatant were transferred onto a streptavidin-coated microplate for quantitation at 405 nm per the manufacturer’s protocol.

Quantitative Real-time PCR

Total RNA was extracted using the RNAsqueous kit (Ambion), per the manufacturer’s protocol. RNA concentrations were determined by spectrophotometry. Reverse transcription/real-time PCRs were done as described (27). The following TaqMan inventoried products were used: PTHrP, Hs00174969_m1; PTH1R, Hs00174895_m1; PI3KCA (PI3K p110α), Hs00180679_m1; integrin α6, Hs00173995_m1; integrin β4, Hs00173995_m1; and the predeveloped 18S rRNA primers (VIC-dye labeled probe, TaqMan assay reagent, P/N 4319413E), and were obtained from Applied Biosystems, as was the universal PCR master mix reagent kit (P/N 4304437).

Measurement of Levels of p-Akt and Total Akt, GSK-3, and c-myc

Cells were plated in 100 mm dishes. When the cells had reached 70% to 80% confluence, they were serum starved for 16 h. FBS (10%) was then added for 30 min, and the cells were processed for Western blot analysis. The following antibodies were used: anti-p-Akt (Ser⁴⁷³) and anti-total Akt (Santa Cruz Biotechnology), anti-GSK-3α/β (Ser²ⁱ/Ser⁴³) and anti-total GSK-3β (Cell Signaling Technology), and anti-c-myc antibody (Santa Cruz Biotechnology).

Anchorage-Independent Cell Growth

Colony formation in soft agar was assayed as described previously (28). Photographs were taken after 2 weeks at high magnification to measure the clone size, using the imaging software ImageJ (NIH). Photographs were also taken at low magnification to measure clone frequency. Five fields per plate were photographed and all clones in focus >50 μm in size were measured. At least two independent experiments were done in triplicate.
Flow Cytometry

Integrin α₆ and β₄ cell-surface levels were measured after staining with R-phycocerythrin-labeled antibodies to the respective subunits, as described [24]. Scans were presented as a comparison with the shift obtained using an isotype control antibody as negative control [24].

Statistics

Numerical data are presented as mean ± SE. Data were analyzed by ANOVA followed by a Bonferroni post-test to determine the statistical significance of differences. All statistical analyses were done using Instat Software (GraphPad Software). P < 0.05 was considered significant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. David Konkel for critical reading of the article.

References

1. Pensone DF, Chan JM. The Urological Diseases in America Project. Prostate cancer. J Urol 2007;177:2020–9.
2. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 1995;153:1085–96.
3. Iwamura M, Wu R, Abrahamsson PA, di Sant’Agnese PA, Cockett AT, Deftos LJ. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994;43:667–74.
4. Kramer S, Reynolds FJ, Jr., Castillo M, Valenzuela DM, Thorkay M, Serrillo JM. Immunological identification and distribution of parathyroid hormone-like protein polyglyptides in normal and malignant tissues. Endocrinology 1991;128:1927–37.
5. Wu G, Iwamura M, di Sant’Agnese PA, Deftos LJ, Cockett ATK, Gershagen S. Characterization of the cell-specific expression of parathyroid hormone-related protein in normal and neoplastic prostate tissue. Urology 1995;51:110–20.
6. Asadi F, Faraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996;27:1319–23.
7. Hall CL, Bafico A, Dia J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:5564–9.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
9. McConkey DJ, Greene G, Pettaway CA. Androgen-independent cancer metastasis precursor cells. Cancer Res 2005;65:5694–9.
10. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res 2005;65:11230–5.
11. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619–26.
12. Frisch SM, Sереatou RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555–62.
13. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005;65:2378–86.
14. Wu HC, Hisieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LnCaP prostate cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406–12.
15. Thalmann GN, Aneziris PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LnCaP model of human prostate cancer. Cancer Res 1994;54:2577–81.
16. Strewler GI. Mechanisms of disease: the physiology of parathyroid hormone-related protein. N Engl J Med 2000;342:177–85.
17. Mannstadt M, Jüppner H, Gardella TJ. Receptors for PTH and PTHrP. Am J Physiol 1999;277:F665–75.
44. Francke TF, Cantley LC. Apoptosis: a bad kinase makes good. Nature 1997; 390:116–7.
45. Gujral A, Burton DW, Terkeltaub R, Deftsos LJ. Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanisms not mediated by its classical nuclear localization sequence. Cancer Res 2001;61:2282–8.
46. Lam MHC, House CM, Tiganis T, et al. Phosphorylation at the cyclin-dependent kinases site (Thr56) of parathyroid hormone-related protein negatively regulates its nuclear localization. J Biol Chem 1999;274:18559–66.
47. Liao J, McCauley LK. Skeletal metastasis: established and emerging roles of parathyroid hormone-related protein (PTHrP). Cancer Metastasis Rev 2006;25:559–71.
48. Miao D, Su H, He B, et al. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci U S A 2008;105:20309–14.
49. Gambaletta D, Marchetti A, Benedetti L, Mercurio AM, Sacchi A, Falcioni R. Cooperative signaling between α6β4 integrin and ErbB2 receptor is required to promote phosphatidylinositol 3-kinase-dependent adhesion. J Biol Chem 2000;275:10604–10.
50. Folgiero V, Bachelder RE, Bon G, Sacchi G, Falcioni R, Mercurio AM. The α6β4 integrin can regulate ErbB-3 expression: implications for α6β4 signaling and function. Cancer Res 2007;67:1645–52.
51. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107:643–54.
52. Shen X, Falzon M. PTH-related protein upregulates integrin α6β4 expression and activates Akt in breast cancer cells. Exp Cell Res 2006;312:3822–34.
53. Brasier AR, Jamaluddin M, Casola A, Duan W, Shen Q, Garofalo RP. A promoter recruitment mechanism for tumor necrosis factor-α-induced interleukin-8 transcription for type II pulmonary epithelial cells. J Biol Chem 1998;273:3551–61.